Key points from article :
Calico and AbbVie discover ABBV-CLS-484, a potential first-in-class cancer immunotherapy drug.
ABBV-CLS-484 is a dual PTPN2/N1 inhibitor that enhances anti-tumour immunity.
In preclinical studies, ABBV-CLS-484 treatment amplifies the tumour intrinsic response to interferon and increases the activation and function of several immune cell subsets.
ABBV-CLS-484 is currently in a Phase 1 clinical trial in solid tumours.
This discovery is a powerful demonstration of how collaboration can bring together diverse expertise to advance our understanding of disease biology and lead to discoveries that support new treatment strategies for people living with cancer.
Calico is an Alphabet-founded research and development company whose mission is to harness advanced technologies and model systems to increase our understanding of the biology that controls human ageing.
The research was published in the journal Nature.
